Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Renzapride

Drug Profile

Renzapride

Alternative Names: ATL-1251; AZM 112; BRL-24924; Renzapride hydrochloride

Latest Information Update: 01 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Alizyme; EndoLogic; GlaxoSmithKline
  • Class Benzamides; Gastrokinetics; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Gastroparesis
  • Discontinued Gastro-oesophageal reflux; Irritable bowel syndrome

Most Recent Events

  • 26 Jun 2019 Atlantic Healthcare enteres into an agreement with EndoLogic to acquire the global rights of renzapride for the treatment of motility disorders of the gastrointestinal (GI) tract
  • 15 May 2018 Clinical trials in Gastroparesis in USA (PO) before May 2018
  • 18 Aug 2017 EndoLogic is seeking funds for development of renzapride as of 10 Aug 2017. www.endologicusa.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top